Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"HER2-positive breast cancer"”.
-
Metabolic vulnerability in HER2-positive Breast Cancer
… human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
Breast cancer accounts for 522,000 deaths worldwide each year and is the most common cancer in women. It is classified according to the cell of origin and its expression of several receptors: oestrogen and progesterone receptors, and human epidermal growth factor receptor 2 (HER2). Historically, …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
Breast cancer (BC) is the deadliest cancer type in women worldwide with high incidence (11.6%) and mortality (6.9%) rates. Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of BC. HER2 overexpression is also observed in other cancers such as gastric/gastroesophageal, …
-
Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer
<p>HER2-positive breast cancer, which is characterized by the over-expression of the HER2 onco-protein, accounts for approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling …
-
NF1 AS A REGULATOR OF CYTOSKELETON DYNAMICS AND BIOMARKER FOR DECISION-MAKING IN HER2-POSITIVE BREAST CANCER
… mutated gene between metastatic and primary HER2+ breast cancer (BC), so we investigated the biological consequences of NF1 loss on sensitivity to antineoplastic treatment and on the metastatic process. We generated NF1 knockout (KO) HER2+ BC cells (i.e.: BT-474, SK-BR-3, HCC1954) by …
-
A NOVEL, RAS-INDEPENDENT ROLE FOR NF1 IN MICROTUBULE DYNAMICS AND DAMAGE REPAIR DICTATES SENSITIVITY TO T-DM1 IN HER2 POSITIVE BREAST CANCER.
… at the somatic level across multiple tumors. In breast cancer, NF1 LoF has been implicated in resistance to both endocrine and anti-HER2 agents. This has been attributed to the best characterized activity of NF1, its GTPase-activating protein (GAP) function that attenuates RAS signaling. NF1 …
-
Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer
… Deruxtecan, T-DXd, Enhertu) σε ασθενείς με HER2-θετικό καρκίνο του μαστού, εστιάζοντας στην αποτελεσματικότητα, την ασφάλεια και τον ρόλο της στα σύγχρονα θεραπευτικά σχήματα. Μεθοδολογία: Πραγματοποιήθηκε συστηματική αναζήτηση στη βιβλιογραφία σε βάσεις δεδομένων όπως PubMed, Scopus και …
-
An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
… hypothesis is that delineation of the effects of HER2-targeted therapy with the tyrosine kinase inhibitor (TKI) lapatinib, in vitro, and elucidation of the ensuing conformational changes may help understand the molecular activity of lapatinib and elucidate mechanisms of resistance. Clinical …
-
The perioperative setting as a platform for breast cancer biomarker development
Breast cancer is the most common cancer in women, with 2.3 million new cases globally in 2022 (1). ‘Neoadjuvant’ systemic therapy prior to surgery is the standard of care for stage II-III human epidermal growth factor receptor-2 (HER2) positive breast cancer. The identification of predictive …
-
Characterization of Novel Liver X Receptor Inverse Agonist in Breast Cancers
Breast cancer is the second most diagnosed cancer type in women and is responsible for approximately 13% of cancer-related mortalities. Significant advances have been made in breast cancer therapy to date. However, the development of targeted therapies remains essential to overcome the lack of …
-
Pathological response of breast cancer to neo-adjuvant chemotherapy at a single tertiary centre with no access to Trastuzumab
… status as the gold standard in the treatment of breast cancer for eligible patients. While prevailing guidelines advocate for a combined approach involving chemotherapy and Trastuzumab for individuals with HER2-positive breast cancer, Groote Schuur Hospital faces constraints in administering …
-
Utilising recombinant TAPBPR technology to investigate MHC class I peptide editing and therapeutic applications
… human epidermal growth factor receptor 2 (HER2) and characterised their ability to load peptide on MHC-I molecules on HER2-positive breast cancer cells. Secondly, I sought to use the increased efficiency of sTAPBPR-αGFP<sub>NB</sub> to investigate peptide editing on MHC-I molecules with a …
-
Rational design, characterization and in vivo studies of antibody mimics against HER2
<p>Human Epidermal Growth Factor Receptor 2 (HER2) is a cell surface receptor tyrosine kinase and plays a role in the signal pathways leading to cell proliferation and differentiation. Overexpression of HER2 is found in various cancers including breast, ovarian, gastric, colon, and non-small-cell …
-
Engineering therapeutic messenger RNA for triple-negative breast cancer
… therapies are revolutionising the landscape of cancer treatment, providing better therapeutic responses and minimising the adverse effects of conventional treatments such as radiation and chemotherapy. Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancer types and …
-
Role of long non-coding RNAs in breast cancer progression
Breast cancer is the most common cancer in women worldwide. The molecular mechanisms underlying the disease have been extensively studied, leading to dramatic improvements in diagnostic and prognostic approaches. Despite the overall improvements in survival rate, numerous cases of death by breast …